Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

Technology appraisal guidance
Reference number: TA543
Published: 03 October 2018

Evidence

Supporting evidence

Evaluation report
Committee papers (PDF 9.36 MB)

Published:

03 October 2018